MENU
Advertisement
News | April 1, 2026Apr012026
EMBRACE to Study Medtronic’s Symplicity Spyral RDN System With Staged PCI
March 31, 2026—Medtronic announced it is supporting the investigator-initiated EMBRACE trial of the company’s Symplicity Spyral renal denervation (RDN).
News | March 11, 2026Mar112026
Verve’s United States Pilot Trial of Renal Pelvic Denervation Therapy Enrolls First Patient
March 11, 2026—Verve Medical, a developer of noninvasive renal pelvic denervation (RPD) technology, announced the treatment of the first patient in its randomized, double-blinded United States pilot clinical trial for the treatment of uncontrolled hypertension.
Symplicity Spyral RDN Studied in Pooled Analyses From SPYRAL HTN Program
March 11, 2026—New analyses from the SPYRAL HTN clinical study program presented at CRT 2026 reported long-term outcomes with the Symplicity Spyral radiofrequency (RF) renal denervation (RDN) system (Medtronic), including a pooled 3-year efficacy analysis, a study of hypertensive urgencies, and the design of the SPYRAL CARE real-world study.
News | March 2, 2026Mar022026
Otsuka’s Paradise uRDN System Launched in Japan With National Health Insurance Coverage
March 2, 2026—Otsuka Medical Devices Co., Ltd. and Otsuka Pharmaceutical Co., Ltd., announced the commercial launch of the Paradise ultrasound renal denervation (uRDN) system.
News | February 19, 2026Feb192026
Medtronic Secures Japan Reimbursement for Spyral RDN
February 19, 2026—Medtronic plc announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted reimbursement approval for the Symplicity Spyral renal denervation (RDN) system (Medtronic) for the treatment of resistant hypertension.
News | November 17, 2025Nov172025
Neurotronic’s Neuviant Multiorgan Denervation Studied to Treat Type 2 Diabetes and Hypertension
November 17, 2025—Neurotronic, Inc. announced the first clinical outcomes of the NECTAR III and NECTAR IV trials evaluating the company’s Neuviant multiorgan denervation (MDN) system in patients with both type 2 diabetes mellitus (T2DM) and hypertension (HTN).
News | October 26, 2025Oct262025
Long-Term SPYRAL HTN-ON MED Data Presented for Medtronic’s Symplicity Spyral RDN System
October 26, 2025—Medtronic announced that long-term results from its final report of the SPYRAL HTN-ON MED trial showed that patients treated with the company’s radiofrequency-based Symplicity Spyral renal denervation (RDN) procedure experienced significantly greater reductions in blood pressure compared to sham patients through 3 years.
News | September 2, 2025Sep022025
Medtronic’s Symplicity Spyral Renal Denervation System Approved in Japan
September 2, 2025—Medtronic announced that its Symplicity Spyral renal denervation (RDN) system has been approved by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for the treatment of resistant hypertension.
News | August 26, 2025Aug262025
Hemodynamic Effects of AVIM Therapy for Hypertension Analyzed in Pressure-Volume Loop Study
August 26, 2025—Orchestra BioMed Holdings, Inc. announced the publication of data from a pressure-volume (PV) loop study demonstrating favorable hemodynamic effects of atrioventricular interval modulation (AVIM) therapy in pacemaker-indicated patients with uncontrolled hypertension.
News | August 25, 2025Aug252025
Otsuka Medical Devices Announces Japan Approval of Paradise uRDN System
August 25, 2025—Otsuka Medical Devices Co., Ltd. announced that the Paradise ultrasound renal denervation (uRDN) system has received manufacturing and marketing approval in Japan for the treatment of resistant hypertension.
Pulnovo Medical Names Dr. Francis Duhay as Global CMO
August 25, 2025—Pulnovo Medical, a developer of mechanism-driven therapies for pulmonary hypertension and heart failure, announced the appointment of Francis Duhay, MD, as Global Chief Medical Officer. Dr.
News | August 15, 2025Aug152025
Renal Denervation Included in ACC/AHA 2025 High Blood Pressure Guideline
August 15, 2025—The American College of Cardiology (ACC) and the American Heart Association (AHA) separately announced publication of the 2025 multisociety guideline for the prevention, detection, evaluation, and management of high blood pressure in adults.
News | July 10, 2025Jul102025
CMS Seeks Comments on Proposed Decision Memo for RDN to Treat Hypertension
July 10, 2025—The Centers for Medicare & Medicaid Services (CMS) issued a proposed decision memo for its National Coverage Analysis (NCA) of renal denervation (RDN)—including radiofrequency (rfRDN) and ultrasound (uRDN) treatments—for uncontrolled hypertension under Coverage with Evidence Development (CED).
News | July 8, 2025Jul082025
Medtronic’s SPYRAL GEMINI Multiorgan Denervation Study Begins Enrollment
July 7, 2025—Medtronic announced that the first patient has been treated in its SPYRAL GEMINI global pilot study, which will investigate the safety and potential efficacy of multiorgan denervation (MDN) in patients with uncontrolled hypertension (HTN).
News | June 12, 2025Jun122025
ACC and BIDMC Smith Center Collaborate on Renal Denervation Registry
June 10, 2025—The American College of Cardiology (ACC) reported that the Richard A. and Susan F. Smith Center for Outcomes Research at Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts, and ACC are collaborating on a renal denervation (RDN) module that leverages the Smith Center’s RDN Registry and the ACC CathPCI Registry.
News | June 11, 2025Jun112025
Medtronic’s GSR-DEFINE Study of Symplicity Spyral RDN System Enrolls First United States Patient
June 11, 2025—Medtronic announced the treatment of the first patient in the United States in the GSR-DEFINE clinical trial.
News | May 19, 2025May192025
Gradient’s Pulmonary Artery Denervation System Receives FDA Breakthrough Designation
May 19, 2025—Gradient Denervation Technologies, which is based in Paris, France, announced that the company’s pulmonary artery denervation (PADN) system has received FDA Breakthrough Device designation.
News | April 16, 2025Apr162025
Pulnovo’s PADN Catheter Receives CE Mark Clearance Under EU MDR
April 16, 2025—Pulnovo Medical, a China-based developer of medical devices for pulmonary hypertension (PH) and heart failure, announced that its pulmonary artery denervation (PADN) catheter for treating PH has received CE Mark clearance under the European Union Medical Device Regulation.
News | March 3, 2025Mar032025
Boston Scientific to Acquire SoniVie
March 3, 2025—Boston Scientific Corporation announced it has entered into a definitive agreement to acquire SoniVie Ltd., a privately held medical device company that has developed the Tivus intravascular ultrasound system for denervation of renal nerves surrounding blood vessels to treat a variety of hypertensive disorders.
News | March 2, 2025Mar022025
Pulnovo Medical Closes Series C Financing to Advance Trials of PADN Technology
March 2, 2025—Pulnovo Medical announced the closing of approximately $100 million Series C financing.
Sponsored by Recor Medical
The Power of 360° Ultrasound Renal Denervation for Blood Pressure Reduction
Exploring the mechanism of action, workflow, and overall benefits of the Paradise® Ultrasound Renal Denervation System for fast, safe blood pressure control.
With Sripal Bangalore, MD, MHA
July/August 2025
Expanding Horizons in Interventional Cardiology
Insights into the necessary skills and collaborations for success in 2025 and beyond.
View Issue
May/June 2024
Technical Essentials
Techniques, tips, and tricks to help you make a difference.
September/October 2023
Modern Clinical Trials Spotlight
Insights on current trial designs, inclusivity, and next steps.
May/June 2023
Team-Based Approaches
How multidisciplinary arrangements facilitate better outcomes.
January/February 2023
Women’s Heart Health
Understanding unique considerations and improving access to care.
September/October 2022
Contemporary Mitral & Tricuspid Therapies
Plus: Exploring Renal Denervation
Renal Denervation: What Is on the Horizon?
With Krishna Rocha-Singh, MD; Farrell O. Mendelsohn, MD; and Ajay J. Kirtane, MD, SM, FACC, FSCAI
Neuromodulation in Heart Failure: Proven and Emerging Solutions
By Felix Götzinger, MD; Lucas Lauder, MD; and Felix Mahfoud, MD, MA
Catheter-Based Renal Denervation
By Anna K. Krawisz, MD, and Eric A. Secemsky, MD, MSc, RPVI, FACC, FSCAI, FSVM